Chronotherapy in Children With Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-30

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot, crossover trial in which the investigator will determine if retiming of one anti-hypertensive medication from morning to evening can effectuate normal blood pressure dipping patterns in children and adolescents with chronic kidney disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients

NCT00221845

Children Chronic Renal Failure Hypertension +2 more

COMPLETED PHASE3

Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients

NCT01007994

Hypertension Secondary to Kidney Transplant

COMPLETED PHASE2/PHASE3

A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD

NCT01750294

Chronic Kidney Disease Poorly-Controlled Hypertension

COMPLETED PHASE4

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171

Hypertension Renal Transplant

WITHDRAWN PHASE1/PHASE2

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

NCT01491919

Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Normally blood pressure declines by at least 10% from daytime to nighttime. In children with chronic kidney disease (CKD), often this does not happen (termed "non-dipping"). This study is a pilot, randomized cross-over trial. The main purpose of this study is to investigate whether non-dipping can be modified with retiming of anti-hypertensives in children with CKD. This is important because in adults, non-dipping has been associated with increased cardiovascular disease risk and more rapid progression of kidney disease. Thus, identification of how to modify this in children with CKD, may lead to future randomized controlled trials to evaluate whether chronotherapy improves outcomes in this population, which is at high risk for morbidity and mortality in adulthood.

The primary objective of this study is to determine whether retiming of one anti-hypertensive to the evening will increase nocturnal systolic blood pressure change (%) in children with CKD, hypertension and non-dipping.

The secondary objective of this study is to determine whether retiming of one anti-hypertensive to the evening will increase nocturnal diastolic blood pressure change (%) in children with CKD, hypertension and non-dipping. Another secondary objective is to determine if the proportion of subjects classified as having a non-dipping pattern is significantly lower on evening dosing of anti-hypertensives.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Diseases Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nighttime dosing of one anti-hypertensive medication

13 participants will be randomized to nighttime dosing of one anti-hypertensive medication. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.

Group Type EXPERIMENTAL

Re-timing of anti-hypertensive drug

Intervention Type OTHER

The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose

remain on their current regimen

13 participants will be randomized to remain on their current regimen. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.

Group Type ACTIVE_COMPARATOR

Current regimen

Intervention Type OTHER

The participants will begin on their current regimen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Re-timing of anti-hypertensive drug

The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose

Intervention Type OTHER

Current regimen

The participants will begin on their current regimen.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female child/adolescent up to 18 years of age with CKD
* estimated glomerular filtration rate (eGFR) of 30 to 90 ml/min/1.73 m2
* diagnosed with hypertension and on a stable dose of anti-hypertensive medication(s) for at least 3 months
* Non-dipping identified on ABPM

Exclusion Criteria

* history of organ transplantation, oncological disease, or dialysis
* inability to complete 24-hour ABPM or 24-hour urine collection
* Children less than 6 years of age will be excluded, as they often are unable to complete a successful ABPM study (≥ 40 readings, with 1 reading per hour of sleep)
* Currently on diuretic medications.

Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No